Table of Contents

1 Study Coverage

• 1.1 Etanercept Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Etanercept Market Size Growth Rate by Product
  • 1.4.2 Benepali
  • 1.4.3 Enbrel
  • 1.4.4 Others
• 1.5 Market by End User
  • 1.5.1 Global Etanercept Market Size Growth Rate by End User
  • 1.5.2 Arthritis
  • 1.5.3 Psoriasis
  • 1.5.4 Spondylitis
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Etanercept Market Size
  • 2.1.1 Global Etanercept Revenue 2014-2025
  • 2.1.2 Global Etanercept Sales 2014-2025
• 2.2 Etanercept Growth Rate by Regions
  • 2.2.1 Global Etanercept Sales by Regions
  • 2.2.2 Global Etanercept Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Etanercept Sales by Manufacturers
  • 3.1.1 Etanercept Sales by Manufacturers
  • 3.1.2 Etanercept Sales Market Share by Manufacturers
  • 3.1.3 Global Etanercept Market Concentration Ratio (CR5 and HHI)
• 3.2 Etanercept Revenue by Manufacturers
  • 3.2.1 Etanercept Revenue by Manufacturers (2014-2019)
  • 3.2.2 Etanercept Revenue Share by Manufacturers (2014-2019)
• 3.3 Etanercept Price by Manufacturers
• 3.4 Etanercept Manufacturing Base Distribution, Product Types
  • 3.4.1 Etanercept Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Etanercept Product Type
  • 3.4.3 Date of International Manufacturers Enter into Etanercept Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Etanercept Sales by Product
• 4.2 Global Etanercept Revenue by Product
• 4.3 Etanercept Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Etanercept Breakdown Data by End User

6 North America

• 6.1 North America Etanercept by Countries
  • 6.1.1 North America Etanercept Sales by Countries
  • 6.1.2 North America Etanercept Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Etanercept by Product
• 6.3 North America Etanercept by End User

7 Europe

• 7.1 Europe Etanercept by Countries
  • 7.1.1 Europe Etanercept Sales by Countries
  • 7.1.2 Europe Etanercept Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Etanercept by Product
• 7.3 Europe Etanercept by End User

8 Asia Pacific

• 8.1 Asia Pacific Etanercept by Countries
  • 8.1.1 Asia Pacific Etanercept Sales by Countries
  • 8.1.2 Asia Pacific Etanercept Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Etanercept by Product
• 8.3 Asia Pacific Etanercept by End User

9 Central & South America

• 9.1 Central & South America Etanercept by Countries
  • 9.1.1 Central & South America Etanercept Sales by Countries
  • 9.1.2 Central & South America Etanercept Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Etanercept by Product
• 9.3 Central & South America Etanercept by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Etanercept by Countries
  • 10.1.1 Middle East and Africa Etanercept Sales by Countries
  • 10.1.2 Middle East and Africa Etanercept Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Etanercept by Product
• 10.3 Middle East and Africa Etanercept by End User

11 Company Profiles

• 11.1 Pfizer
  • 11.1.1 Pfizer Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Pfizer Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Pfizer Etanercept Products Offered
  • 11.1.5 Pfizer Recent Development
• 11.2 Takeda
  • 11.2.1 Takeda Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Takeda Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Takeda Etanercept Products Offered
  • 11.2.5 Takeda Recent Development
• 11.3 Johnson & Johnson
  • 11.3.1 Johnson & Johnson Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Johnson & Johnson Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Johnson & Johnson Etanercept Products Offered
  • 11.3.5 Johnson & Johnson Recent Development
• 11.4 GlaxoSmithKline
  • 11.4.1 GlaxoSmithKline Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 GlaxoSmithKline Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 GlaxoSmithKline Etanercept Products Offered
  • 11.4.5 GlaxoSmithKline Recent Development
• 11.5 Samsung Bioepis
  • 11.5.1 Samsung Bioepis Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Samsung Bioepis Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Samsung Bioepis Etanercept Products Offered
  • 11.5.5 Samsung Bioepis Recent Development
• 11.6 Roche
  • 11.6.1 Roche Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Roche Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Roche Etanercept Products Offered
  • 11.6.5 Roche Recent Development
• 11.7 Cipla
  • 11.7.1 Cipla Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Cipla Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Cipla Etanercept Products Offered
  • 11.7.5 Cipla Recent Development
• 11.8 Novartis
  • 11.8.1 Novartis Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Novartis Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Novartis Etanercept Products Offered
  • 11.8.5 Novartis Recent Development
• 11.9 Celltrion
  • 11.9.1 Celltrion Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Celltrion Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Celltrion Etanercept Products Offered
  • 11.9.5 Celltrion Recent Development
• 11.10 Immunex
  • 11.10.1 Immunex Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Immunex Etanercept Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Immunex Etanercept Products Offered
  • 11.10.5 Immunex Recent Development

12 Future Forecast

• 12.1 Etanercept Market Forecast by Regions
  • 12.1.1 Global Etanercept Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Etanercept Revenue Forecast by Regions 2019-2025
• 12.2 Etanercept Market Forecast by Product
  • 12.2.1 Global Etanercept Sales Forecast by Product 2019-2025
  • 12.2.2 Global Etanercept Revenue Forecast by Product 2019-2025
• 12.3 Etanercept Market Forecast by End User
• 12.4 North America Etanercept Forecast
• 12.5 Europe Etanercept Forecast
• 12.6 Asia Pacific Etanercept Forecast
• 12.7 Central & South America Etanercept Forecast
• 12.8 Middle East and Africa Etanercept Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Etanercept Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Etanercept are biopharmaceutical anti-Tumor Necrosis Factor (TNF) that treats autoimmune diseases such as arthritis and spondylitis.
The production of TNF in the body causes inflammation, pain, and damage to the bones and joints. Etanercept blocks the action of TNF and reduces the inflammation. It is prescribed to treat juvenile rheumatoid arthritis, rheumatoid arthritis, and psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
The global Etanercept market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Etanercept market based on company, product type, end user and key regions.

This report studies the global market size of Etanercept in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Etanercept in these regions.
This research report categorizes the global Etanercept market by top players/brands, region, type and end user. This report also studies the global Etanercept market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Takeda
Johnson & Johnson
GlaxoSmithKline
Samsung Bioepis
Roche
Cipla
Novartis
Celltrion
Immunex

Market size by Product
Benepali
Enbrel
Others
Market size by End User
Arthritis
Psoriasis
Spondylitis

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Etanercept market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Etanercept market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Etanercept companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Etanercept submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Etanercept are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Etanercept market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.